Digital therapeutics – clinical-grade software used to prevent, treat, or manage a medical disorder or disease - are redefining the future of healthcare. They greatly improve access to care, quality of care, and treatment outcomes, while reducing costs for a wide array of clinical populations.

In recent years, we have experienced a surge in demand for remote models of healthcare, exponential growth in the digital health industry, a growing array of models of deploying digital therapeutics and an evolving payor landscape.

This Summit will provide an overview of innovations in scientific discovery, clinical applications and global deployment of digital therapeutics.

It will highlight the perspectives of individuals from diverse sectors - including researchers, healthcare providers and administrators, regulators, payors, and investors, as well as the digital health industry and global pharma engaged in building digital health formularies.

The goal is for this dialogue to help shape a vision for the future of how the most effective and engaging digital therapeutics can be accessible to people all over the globe.

Event Location: Hanover Inn Dartmouth, 2 E Wheelock St, Hanover, NH 03755

Lodging: A block of rooms is being held at Hanover Inn Dartmouth for the nights of 10/24 and 10/25, under "Digital Health Summit Call-In Block." Individuals can call  (603) 643-4300 to reserve. Please note that rooms are limited, so reservations should be made as soon as possible.

8:00-8:45 am: Registration and Breakfast

8:45-9:15 am: Welcome and Introduction to the Summit (Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

9:15-9:45 am: Clinically-Validated Digital Therapeutics Research: Priorities for Development, Evaluation, and Implementation at the National Institute on Drug Abuse (Jia Bei Wang, National Institute on Drug Abuse)

9:45-10:15 am: US Food and Drug Administration’s (FDA) Digital Health Center of Excellence: Mission and Vision for the Future (Gioia Guerrieri, Medical Officer, FDA Digital Health Center of Excellence)

10:15-10:45 am: Coffee Break

10:45-11:00 am: Welcome Remarks (Sian Beilock, President, Dartmouth College)

11:00-11:30 am: The Current State of Digital Therapeutics in the US and across the Globe (Andy Molnar, Chief Executive Officer, Digital Therapeutics Alliance)

11:30-12:00 pm: An Update on Global Regulatory Affairs in Digital Therapeutics (Marty Culjat, Senior Vice President, Global Head of Digital Medicine and Regulatory Innovation, EVERSANA)

12:00-1:00 pm: Lunch

1:00-2:15 pm: The Value Proposition of Digital Therapeutics: A Panel Discussion on Various paths to Deployment and Strategies to Achieve Payor Buy-In

Facilitator: Rob O’Brien, Senior Vice President, Real Endpoint

Panelists:

• Jason Parent, Director, Clinical Innovation, Point32Health
• Jeff Abraham, Partner, Health Advances
• Reena Pande, Former CMO, AbleTo
• Brendan Hare, Senior Associate Director, Clinical Development and Medical Affairs, Boehringer Ingelheim

2:15-2:30 pm: Coffee Break

2:30-3:45 pm: The Role of Global Pharma in Scaling Evidence-based Digital Therapeutics

Facilitator: Rich DeNunzio, Chief Commercial Officer, Click Therapeutics

Panelists:

• Abishek Pratap, Senior Clinical Program Leader, CNS, Boehringer Ingelheim
• Bill Rush, Senior Director, Digital Healthcare Solutions, Sanofi
• Daniel Carpenter, Senior Director, Digital Therapeutics Product Manager, Otsuka Pharmaceutical Companies

3:45-4:45 pm: A Snapshot of Innovations in Digital Health at the Center for Technology and Behavioral Health at Dartmouth College

• 3:45-4:00 pm: Integrated Digital Care for Patients in Treatment for Opioid Use Disorder: Digital Phenotyping, Mobile Interventions, and Mental Health Outcomes (Lisa Marsch and Nicholas Jacobson, Center for Technology and Behavioral Health, Dartmouth College)
• 4:00-4:15 pm: SweetGoals: A Digital Health Intervention for Young Adults With Type 1 Diabetes (Cathy Stanger, Professor, Center for Technology and Behavioral Health, Dartmouth College)
• 4:15-4:30 pm: Using Generative Artificial Intelligence for Mental Health Assessment and Treatment (Nicholas Jacobson and Michael Heinz, Center for Technology and Behavioral Health, Dartmouth College)
•  4:30-4:45 pm: The Dartmouth Innovation Accelerator in Digital Health (DIADH) (Barry Schweitzer, Associate Director, Magnuson Center for Entrepreneurship, Dartmouth College)

4:45-4:50 pm: Concluding Comments (Lisa Marsch, Director, Center for Technology and Behavioral Health at Dartmouth College)

4:50-6:30 pm: Reception and CTBH & DIADH poster/demo session